Alex Cherry serves as the Vice President of Clinical Innovation & Partnerships at Cornerstone Specialty Network, LLC.
Alex brings more than 25 years of experience across pharma and healthcare, with leadership roles spanning oncology, hematology, and rare diseases. Prior to joining Cornerstone, she held senior executive roles at Pfizer, including Vice President of Global Marketing for Hematology and Vice President, Emerging Markets Group Lead for Rare Disease and Hospital, where she led global commercialization, portfolio expansion, and launch strategy for innovative therapies across complex therapeutic areas. Earlier in her career, Alex held commercial leadership roles at Eisai, Cephalon, and Johnson & Johnson.
Throughout her career, Alex has worked at the intersection of commercial strategy, clinical engagement, and evidence generation, partnering closely with medical affairs, clinical development, and HEOR teams to inform target product profiles, support real-world evidence initiatives, and shape physician education and market-shaping strategies for first-in-class and science-driven therapies.
At Cornerstone, Alex focuses on building real-world evidence and clinical insight programs grounded in community oncology practice and shaping collaboration between pharma and community oncologists to support clinically meaningful, evidence-driven care.
